Table 3.
Demographics and clinical data for the validation cohort septic shock subclasses based on the majority call of 21 clinical evaluators.1
| Subclass A | Subclass B | Subclass C | P value | |
|---|---|---|---|---|
| No. of patients | 25 | 28 | 29 | -- |
| Median age in years (IQR)2 | 1.0 (0.2–3.1) | 5.7 (1.0–8.6) | 2.0 (1.3–5.4) | 0.005 |
| No. of males/females | 17/8 | 19/9 | 21/8 | 0.915 |
| No. of deaths (%) | 5 (20)3 | 4 (14) | 3 (10) | 0.520 |
| Maximum # of organ failures (IQR) 4 | 3 (2–4) | 2 (2–3) | 2 (2–3) | 0.032 |
| Median PRISM score (IQR) | 17 (11–28) | 11 (7–14) | 14 (9–17) | 0.014 |
| Median PICU free days (IQR) | 15 (1–20) | 21 (13–23) | 17 (9–24) | 0.191 |
| No. with co-morbidity (%)5 | 7 (28) | 16 (57) | 10 (34) | 0.071 |
| No. with immune suppression (%)6 | 1 (4) | 3 (11) | 3 (10) | 0.627 |
| No. receiving hydrocortisone (%)7 | 7 (28) | 16 (57) | 11 (36) | 0.088 |
| No. with gram pos. bacteria (%)8 | 8 (32) | 7 (25) | 9 (31) | 0.827 |
| No. with gram neg. bacteria (%) | 8 (32) | 8 (29) | 10 (34) | 0.891 |
| No. with negative cultures (%) | 6 (24) | 10 (36) | 9 (31) | 0.650 |
| Median WBC count × 103/mm3 (IQR) | 10 (4–14) | 16 (11–24) | 15 (6–18) | 0.009 |
| Median neutrophil count × 103/mm3 (IQR) | 7 (1–11) | 12 (8–21) | 10 (4–16) | 0.006 |
| Median lymphocyte count × 103/mm3 (IQR) | 1.8 (1.0–4.1) | 2.4 (0.9–3.5) | 1.6 (0.9–3.8) | 0.945 |
| Median monocyte count × 103/mm3 (IQR) | 0.5 (0.4–1.0) | 0.7 (0.3–1.0) | 0.5 (0.2–1.2) | 0.952 |
Continuous variables are analyzed as 3 group comparisons using ANOVA on Ranks and 2 degrees of freedom. Proportions are analyzed as 3 group comparisons using a 2 by 3 contingency table and Chi-square with 2 degrees of freedom.
Interquartile range (IQR).
Odds ratio for mortality vs. Subclass B: 1.5 (0.4–4.6); vs. Subclass C: 2.2 (0.5–10.2).
Refers to the maximum number of organ failures during the initial 7 days of PICU admission.
Refers to patients having any major diagnosis in addition to septic shock (e.g. trauma, sickle cell disease, congenital heart disease, liver failure, etc.)
Refers to patients with immune deficiency secondary to an intrinsic documented defect of the immune system, or patients receiving immune-suppressive medications (e.g. calcineurin inhibitors or high dose steroids).
For cardiovascular shock.
All bacterial culture data refer to samples obtained from bodily fluids that are normally sterile (i.e. blood, urine, cerebral spinal fluid, broncho-alveolar lavage, and/or peritoneal fluid).